The 4.73x EV/EBITDA multiple is only superficially cheap against peers, because trailing EBITDA still embeds the pre-impairment asset base while enterprise value now sits against a 25% smaller balance sheet; the 3.51x forward figure is similarly suspect without a reported actual EPS against the $2.92 consensus. We would treat the 2.89x P/FCF as the more defensible anchor, though the 9.0% FCF margin in 2026Q3 rested partly on working capital release, so investors should monitor whether the multiple gap versus IBEX (10.22x) reflects genuine value or a durably impaired franchise.

The stability of the gross margin — holding a 33–36% band across all ten quarters despite the Webhelp integration — suggests client pricing has broadly kept pace with wage inflation, so the -40.3% net margin appears dominated by amortization and write-downs rather than a loss of pricing power. We would anchor true earning power on pre-impairment operating income near $120–145M per quarter rather than the reported bottom line, while flagging that the 2025Q4 gross margin dip to 27.9% shows the delivery spread is not immune to shock.

Even stripping the impairment quarters entirely, a ~1.2% ROIC on an asset base inflated by $5.2B of goodwill points to an acquisition-led return profile that was decayed rather than compounding, with asset turnover stuck at 0.20–0.25 offering no efficiency offset. This reframes the Webhelp deal as value-dilutive on a returns basis irrespective of the accounting write-down, and investors should watch whether ROIC can be rebuilt through margin expansion rather than further balance-sheet shrinkage.

Because the leverage increase is denominator-driven, the debt service burden has not mechanically worsened — coverage held near 2.0x through the profitable quarters — but the negative coverage print and the absence of a current D/EBITDA reading reduce visibility into covenant headroom. We would characterize refinancing risk as elevated but not acute, contingent on operating income reverting to its historical $120M-plus quarterly run rate; a second consecutive impairment quarter would materially change that assessment.

The valuation gap versus IBEX appears structural rather than temporary, as IBEX pairs its 10.22x multiple with 19.5% ROIC and 0.52x leverage, whereas Concentrix pairs sub-2% historical ROIC with 2.47x debt-to-equity. TTEC's even weaker -142.5% ROE and 8.86x leverage suggest the market is distinguishing between a business undergoing a one-time accounting reset and one with structural demand erosion — a distinction Concentrix's negative organic growth makes uncomfortable to draw in its favor.